Latest Blog Posts Tagged "Funding Priority Area"
March 14, 2018
A study funded by the Foundation suggests a form of non-invasive brain stimulation may help relieve these PD symptoms.
March 09, 2018
More than 40 experts convened at the MJFF offices to discuss how to advance therapies against Parkinson's genetic target GBA.
January 12, 2018
Michael J. Fox Foundation-funded researchers have created exquisitely sensitive antibodies that may help test therapies against a top Parkinson's drug target.
June 13, 2014
A new study shows two avenues through which inhibiting the function of the protein LRRK2 may help treat people with Parkinson's, even those without a LRRK2 genetic mutation.
June 05, 2014
Our monthly roundup of projects that we've recently funded includes ones that span our research portfolio. These grants support work on motor symptoms, cognition and genetics.
April 24, 2014
A new funding program aims to explore which species of the protein alpha-synuclein play a role in the clumps seen in Parkinson's disease.
January 13, 2014
Alpha-synuclein — the protein that clumps in the cells of Parkinson's patients — is a target for disease-modifying therapies. Read about four promising research projects targeting alpha-synuclein....
November 11, 2013
A study testing a new drug to treat levodopa-induced dyskinesia has enrolled its first patient.
March 19, 2013
Today The Foundation and Addex Pharmaceuticals are announcing the next chapter in a continuing partnership around the development of dipraglurant, or "dipra," for the treatment of dyskinesia...
September 06, 2012
The deadline for academic and industry researchers to apply to the Therapeutics Pipeline Program is this coming Wednesday, September 12.